Current Heart Failure Reports

, Volume 6, Issue 4, pp 220-228

First online:

β-Adrenergic receptor blockers and heart failure risk after myocardial infarction: A critical review

  • Robert H. Neumayr
  • , Paul J. HauptmanAffiliated withDivision of Cardiology, FDT-15, Saint Louis University Hospital Email author 

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access


Remodeling after myocardial infarction is a complex biological process that leads to progressive left ventricular dilation and clinical heart failure. Multiple influences, including autonomic imbalance with sympathetic activation, contribute to the process. This article reviews clinical data in favor of early- and long-term use of β-adrenergic receptor blockers in patients after myocardial infarction. Areas of uncertainty, such as the selection of dose and duration of therapy, current guidelines, and patterns of underuse of therapy with this important class of drugs are outlined and highlighted.